To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Monday, March 23, 2020
Sanofi and Regeneron say they have placed...
...their rheumatoid arthritis
medication, Kevzara, into immediate clinical trials in the fight against
COVID-19. The drugmakers will initially focus on Kevzara's effect on fever and
patients' need for supplemental oxygen. For the treatment of rheumatoid
arthritis, Kevzara currently holds preferred status for just 1% of covered
lives, growing to 8% with prior authorization and/or step therapy.
SOURCE: MMIT Analytics, as
of 3/18/20
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment